文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA治疗资格取决于伴随诊断示踪剂的选择:转移性去势抵抗性前列腺癌中68Ga-PSMA-11与99mTc-MIP-1404的比较

Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2022-10-27

本研究比较了68Ga-PSMA-11 PET/CT与99mTc-MIP-1404 SPECT/CT在转移性去势抵抗性前列腺癌患者中的病灶及病灶/正常器官比值。结果显示99mTc-MIP-1404的肝脏SUVmax更高,病灶/肝脏比值更低,提示若用99mTc-MIP-1404评估177Lu-PSMA-617治疗资格,应采用较低的调整后病灶/肝脏比值。

要点

  • 99mTc-MIP-1404 SPECT病灶SUVmax与68Ga-PSMA-11 PET无显著差异(中位数18.2 vs 17.3,P=0.93)。
  • 99mTc-MIP-1404肝脏SUVmax更高(中位数8.5 vs 5.8,P=0.002),病灶/肝脏比值更低(中位数2.7 vs 3.5,P=0.009)。
  • 若用99mTc-MIP-1404评估177Lu-PSMA-617治疗资格,应采用较低的调整后病灶/肝脏比值。

核心结论

  • 68Ga-PSMA-11与99mTc-MIP-1404在生物分布尤其是肝脏活性方面存在差异,若用99mTc-MIP-1404评估177Lu-PSMA-617治疗资格,应采用较低的调整后病灶/肝脏比值。

研究设计与样本

  • 纳入年龄、前列腺特异性抗原水平及Gleason总评分匹配的两组mCRPC患者,分别接受99mTc-MIP-1404 SPECT/CT(n=25)或68Ga-PSMA-11 PET/CT(n=25)扫描。
  • 测量每个部位(前列腺/前列腺床、淋巴结、骨及软组织转移)最多3个病灶以及正常肝脏、腮腺、脾脏和纵隔血池的SUVmax。

主要发现

  • 99mTc-MIP-1404 SPECT病灶SUVmax与68Ga-PSMA-11 PET无显著差异(中位数18.2 vs 17.3,P=0.93)。
  • 99mTc-MIP-1404肝脏SUVmax高于68Ga-PSMA-11(中位数8.5 vs 5.8,P=0.002)。
  • 99mTc-MIP-1404病灶/肝脏比值低于68Ga-PSMA-11(中位数2.7 vs 3.5,P=0.009)。
  • 两种示踪剂的腮腺SUVmax、脾脏SUVmax及病灶/腮腺比值无显著差异,但病灶/脾脏比值存在小差异(P=0.034)。

临床怎么用

  • 若使用99mTc-MIP-1404评估177Lu-PSMA-617治疗资格,应采用较低的调整后病灶/肝脏比值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-prostate-specific membrane antigen-617 (177Lu-PSMA-617) is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC), with evidence of improved survival over standard care. The VISION trial inclusion criteria required a metastatic lesion-to-liver ratio of greater than 1 on 68Ga-PSMA-11 PET scans. We aimed to determine whether an equivalent ratio is suitable for a SPECT tracer, 99mTc-MIP-1404, and to compare lesion and lesion-to-normal-organ ratios between the 2 radiotracers. Methods: Two cohorts of patients with mCRPC matched for age, prostate-specific antigen level, and total Gleason score, with either 99mTc-MIP-1404 SPECT/CT (n = 25) or 68Ga-PSMA-11 PET/CT (n = 25) scans, were included for analysis. Up to 3 lesions in each site (prostate/prostate bed, lymph nodes, bone and soft-tissue metastases) as well as normal liver, parotid gland, spleen, and mediastinal blood-pool SUVmax were measured. Results: 99mTc-MIP-1404 SPECT lesion SUVmax was not significantly different from 68Ga-PSMA-11 PET (median, 18.2 vs. 17.3; P = 0.93). However, 99mTc-MIP-1404 liver SUVmax was higher (median, 8.5 vs. 5.8; P = 0.002) and lesion-to-liver ratios were lower (median, 2.7 vs. 3.5; P = 0.009). There was no significant difference in parotid gland or splenic SUVmax or lesion-to-parotid gland ratios between the 2 tracers although there was a small difference in lesion-to-spleen ratios (P = 0.034). Conclusion: There are differences in biodistribution and, in particular, liver activity, between 68Ga-PSMA-11 and 99mTc-MIP-1404. Therefore, if 99mTc-MIP-1404 is used to assess eligibility for 177Lu-PSMA-617 therapy, a lower adjusted lesion-to-liver ratio should be used.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cook GJR, Wong WL, Sanghera B, et al. Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2022. PMID: 36302657. doi:10.2967/jnumed.122.264296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。